异源与同源新冠疫苗方案有效性的活系统评价与网络Meta分析
该活系统评价与网络Meta分析检索了2022年3月8日至7月31日世界卫生组织新冠数据库中的63项研究,评估异源与同源新冠疫苗方案在有或无加强针时预防感染、住院和死亡的有效性。三剂mRNA疫苗对非德尔塔或非奥密克戎相关感染的有效性为93%,对住院为96%。作者的结论是推荐用mRNA加强针补充任何基础免疫程序。
要点
- 三剂mRNA疫苗对非德尔塔或非奥密克戎相关感染的有效性为93%(95%可信区间70%至98%)。
- 两剂腺病毒载体疫苗加一剂mRNA异源加强对非德尔塔或非奥密克戎相关感染的有效性为94%(72%至99%)。
- 针对德尔塔或奥密克戎相关感染,两剂腺病毒载体疫苗加一剂mRNA加强的有效性为77%(42%至91%)。
核心结论
- 作者推荐用mRNA加强针补充任何基础免疫程序。
- 异源与同源三剂方案在预防新冠感染方面效果相当,即使针对不同变异株也是如此。
- 三剂疫苗方案对新冠相关死亡的有效性仍不确定。
研究设计与样本
- 活系统评价与网络Meta分析,纳入随机对照试验、队列研究和病例对照研究。
- 检索世界卫生组织新冠数据库的38个来源,包括已发表研究和预印本,检索时间为2022年3月8日至2022年7月31日,每周检索一次。
- 第二次分析纳入63项研究,识别出25种新冠疫苗方案组合。
- 主要指标为疫苗有效性,计算方式为1减比值比;次要指标为累积排序曲线下面积(SUCRA)评分和两两比较的相对效应。
- 采用ROBINS-I工具评估队列和病例对照研究的偏倚风险,采用Cochrane偏倚风险工具第2版(ROB-2)评估随机对照试验。
主要发现
- 三剂mRNA疫苗对非德尔塔或非奥密克戎相关无症状或症状性感染的有效性为93%(95%可信区间70%至98%)。
- 两剂腺病毒载体疫苗加一剂mRNA异源加强对非德尔塔或非奥密克戎相关无症状或症状性感染的有效性为94%(72%至99%)。
- 三剂mRNA疫苗在减少非德尔塔或非奥密克戎相关住院方面最有效,有效性为96%(82%至99%)。
- 针对德尔塔或奥密克戎相关感染,两剂腺病毒载体疫苗加一剂mRNA加强的无症状或症状性感染有效性为77%(42%至91%),三剂mRNA疫苗对新冠相关住院的有效性为93%(76%至98%)。
- 四剂mRNA疫苗方案的估计为低确定性,因为本次更新仅纳入一项关于四剂有效性的研究。
关键数值与推荐
- 作者推荐用mRNA加强针补充任何基础免疫程序。
- 三剂mRNA疫苗对非德尔塔或非奥密克戎相关感染的有效性为93%(95%可信区间70%至98%)。
- 两剂腺病毒载体疫苗加一剂mRNA异源加强对非德尔塔或非奥密克戎相关感染的有效性为94%(72%至99%)。
- 三剂mRNA疫苗对非德尔塔或非奥密克戎相关住院的有效性为96%(82%至99%)。
- 针对德尔塔或奥密克戎相关感染,两剂腺病毒载体疫苗加一剂mRNA加强的有效性为77%(42%至91%),三剂mRNA疫苗对住院的有效性为93%(76%至98%)。
临床怎么用
- 作者推荐用mRNA加强针补充任何基础免疫程序。
- 异源与同源三剂方案在预防新冠感染方面效果相当,即使针对不同变异株也是如此。
- 三剂疫苗方案对新冠相关死亡的有效性仍不确定。
- 四剂mRNA疫苗方案的有效性为低确定性,需要更多关于四剂方案的证据来准确评估第四剂疫苗的有效性。
局限性
- 三剂mRNA疫苗对死亡的有效性因混杂因素仍不确定。
- 四剂mRNA疫苗方案的估计为低确定性,因为本次更新仅纳入一项关于四剂有效性的研究。
- 需要更多关于四剂方案的证据来准确评估第四剂疫苗的有效性。
- 本综述未注册。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness of heterologous and homologous covid-19 vaccine regimens with and without boosting in preventing covid-19 related infection, hospital admission, and death. DESIGN: Living systematic review and network meta-analysis. DATA SOURCES: World Health Organization covid-19 databases, including 38 sources of published studies and preprints. STUDY SELECTION: Randomised controlled trials, cohort studies, and case-control studies. METHODS: 38 WHO covid-19 databases were searched on a weekly basis from 8 March 2022 to 31 July 2022. Studies that assessed the effectiveness of heterologous and homologous covid-19 vaccine regimens with or without a booster were identified. Studies were eligible when they reported the number of documented, symptomatic, severe covid-19 infections, covid-19 related hospital admissions, or covid-19 related deaths among populations that were vaccinated and unvaccinated. The primary measure was vaccine effectiveness calculated as 1−odds ratio. Secondary measures were surface under the cumulative ranking curve (SUCRA) scores and the relative effects for pairwise comparisons. The risk of bias was evaluated by using the risk of bias in non-randomised studies of interventions (ROBINS-I) tool for all cohort and case-control studies. The Cochrane risk of bias tool (version 2; ROB-2) was used to assess randomised controlled trials. RESULTS: The second iteration of the analysis comprised 63 studies. 25 combinations of covid-19 vaccine regimens were identified, of which three doses of mRNA vaccine were found to be 93% (95% credible interval 70% to 98%) effective against asymptomatic or symptomatic covid-19 infections for non-delta or non-omicron related infections. Heterologous boosting using two dose adenovirus vector vaccines with one dose mRNA vaccine showed a vaccine effectiveness of 94% (72% to 99%) against non-delta or non-omicron related asymptomatic or symptomatic infections. Three doses of mRNA vaccine were found to be the most effective in reducing non-delta or non-omicron related hospital admission (96%, 82% to 99%). The vaccine effectiveness against death in people who received three doses of mRNA vaccine remains uncertain owing to confounders. The estimate for a four dose mRNA vaccine regimen was of low certainty, as only one study on the effectiveness of four doses could be included in this update. More evidence on four dose regimens will be needed to accurately assess the effectiveness of a fourth vaccine dose. For people with delta or omicron related infection, a two dose regimen of an adenovirus vector vaccine with one dose of mRNA booster was 77% (42% to 91%) effective against asymptomatic or symptomatic covid-19 infections, and a three dose regimen of a mRNA vaccine was 93% (76% to 98%) effective against covid-19 related hospital admission. CONCLUSION: An mRNA booster is recommended to supplement any primary vaccine course. Heterologous and homologous three dose regimens work comparably well in preventing covid-19 infections, even against different variants. The effectiveness of three dose vaccine regimens against covid-19 related death remains uncertain. SYSTEMATIC REVIEW REGISTRATION: This review was not registered. The protocol is included in the supplementary document. READERS' NOTE: This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication. This version is update 1 of the original article published on 31 May 2022 (BMJ 2022;377:e069989), and previous versions can be found as data supplements (https://www.bmj.com/content/377/bmj-2022-069989/related). When citing this paper please consider adding the version number and date of access for clarity.
引用
- Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022. PMID: 35640925. doi:10.1136/bmj-2022-069989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。